Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
QTX3034
i
Other names:
QTX3034
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Quanta Therap
Drug class:
KRAS G12D inhibitor, KRAS inhibitor
Related drugs:
‹
MRTX1133 (8)
KS-58 (3)
RMC-9805 (2)
QTX3046 (1)
YL-17231 (1)
HRS-4642 (0)
Undisclosed MSC-derived Exosomes with KrasG12D siRNA (0)
MRTX1257 (4)
AZD4785 (1)
ATG-012 (0)
ELI-002 7P (0)
KRAS peptide vaccine (0)
SLATE-KRAS (0)
anti-KRAS G12D mTCR PBL (0)
mRNA-5671 (0)
siG12D LODER (0)
MRTX1133 (8)
KS-58 (3)
RMC-9805 (2)
QTX3046 (1)
YL-17231 (1)
HRS-4642 (0)
Undisclosed MSC-derived Exosomes with KrasG12D siRNA (0)
MRTX1257 (4)
AZD4785 (1)
ATG-012 (0)
ELI-002 7P (0)
KRAS peptide vaccine (0)
SLATE-KRAS (0)
anti-KRAS G12D mTCR PBL (0)
mRNA-5671 (0)
siG12D LODER (0)
›
Associations
(1)
News
Trials
Filter by
Latest
9ms
QTX3034-001: QTX3034 in Patients With KRAS G12D Mutation (clinicaltrials.gov)
P1, N=250, Recruiting, Quanta Therapeutics | Not yet recruiting --> Recruiting
9 months ago
Enrollment open
|
KRAS (KRAS proto-oncogene GTPase)
|
Erbitux (cetuximab) • QTX3034
10ms
QTX3034-001: Evaluate QTX3034 in Patients With KRAS G12D Mutation (clinicaltrials.gov)
P1, N=250, Not yet recruiting, Quanta Therapeutics
10 months ago
New P1 trial
|
KRAS (KRAS proto-oncogene GTPase)
|
Erbitux (cetuximab) • QTX3034
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login